Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-03
DOI
10.1038/s41388-018-0421-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
- (2016) Andrew R Green et al. BRITISH JOURNAL OF CANCER
- Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
- (2016) Priyanka Sharma et al. CLINICAL CANCER RESEARCH
- Resetting cancer stem cell regulatory nodes upon MYC inhibition
- (2016) Silvia Galardi et al. EMBO REPORTS
- The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
- (2016) H. K. Bid et al. MOLECULAR CANCER THERAPEUTICS
- Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide
- (2016) A. Sorolla et al. Nanoscale
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
- (2016) Roman Camarda et al. NATURE MEDICINE
- OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors
- (2016) L A Jung et al. ONCOGENE
- Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms
- (2016) Xiarong Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Different promoter affinities account for specificity in MYC-dependent gene regulation
- (2016) Francesca Lorenzin et al. eLife
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Small-molecule inhibitors of the Myc oncoprotein
- (2015) Steven Fletcher et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas
- (2015) Munevver Cinar et al. LEUKEMIA RESEARCH
- Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP
- (2015) Liangliang Shen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
- (2015) Maria Patrizia Mongiardi et al. Scientific Reports
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer
- (2014) Dimitris Stellas et al. JNCI-Journal of the National Cancer Institute
- Inhibitor of MYC identified in a Krohnke pyridine library
- (2014) J. R. Hart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
- (2014) Daniela Annibali et al. Nature Communications
- Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
- (2013) L. Soucek et al. GENES & DEVELOPMENT
- Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function
- (2013) A S Beltran et al. ONCOGENE
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
- (2012) P. J. Roberts et al. CLINICAL CANCER RESEARCH
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
- (2011) N. Palaskas et al. CANCER RESEARCH
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
- (2011) T. W. Miller et al. CLINICAL CANCER RESEARCH
- The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy
- (2011) Mauro Savino et al. PLoS One
- In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization
- (2010) D. M. Clausen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- MYC regulation of a “poor-prognosis” metastatic cancer cell state
- (2010) Anita Wolfer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phenotypic screening of phylomer peptide libraries derived from genome fragments to identify and validate new targets and therapeutics
- (2009) Paul M Watt Future Medicinal Chemistry
- Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice
- (2008) Jianxia Guo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
- (2008) M. N. Dickler et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now